IP Library › Granted Patent US 9,926,314
Granted Patent B2
US 9,926,314 · App. 15/220,149 · Granted Mar 27, 2018

Compounds and compositions for the treatment of parasitic diseases

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,926,314
App. No.
15/220,149
Granted
Mar 27, 2018
Kind
B2
Abstract

The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.

Claims (22)

1. A compound selected from:

or a pharmaceutical acceptable salt thereof.

2. A method for treating, preventing, inhibiting, ameliorating, or eradicating malaria, comprising administering to a subject a therapeutically effective amount of a compound according to claim 1 , wherein the administering may be in combination with a second agent.

3. The method according to claim 2 , wherein the malaria is caused by a Plasmodium parasite, and wherein the Plasmodium parasite is at the blood stages or the hepatic stages.

4. A pharmaceutical composition comprising at least one compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

5. A method for treating, preventing, inhibiting, ameliorating, or eradicating malaria, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition according to claim 4 , wherein the administering may be in combination with a second agent.

6. The method according to claim 5 , wherein the second agent is for the treatment of malaria.

7. The method according to claim 5 , wherein the second agent is an antimalarial drug selected from artemisinin, artemether, artesunate, arteflene, dihydroartemisinin, chlorproguanil, trimethoprim, chloroquine, quinine, mefloquine, amodiaquine, atovaquone, proguanil, lumefantrine, piperaquine, pyronaridine, halofantrine, pyrimethamine-sulfadoxine, quinacrine, pyrimethamine-dapsone, quinidine, amopyroquine, sulphonamides, primaquine, ferroquine, tafenoquine, arterolane, and pyronaridine.

8. A compound of formula:

or a pharmaceutical acceptable salt thereof.

9. A compound of formula:

or a pharmaceutical acceptable salt thereof.

10. A pharmaceutical composition comprising compound of claim 8 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

11. A pharmaceutical composition comprising compound of claim 9 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent or excipient.

12. A method for treating, preventing, inhibiting, ameliorating, or eradicating malaria, comprising administering to a subject a therapeutically effective amount of a compound according to claim 8 , wherein the administering may be in combination with a second agent.

13. A method for treating, preventing, inhibiting, ameliorating, or eradicating malaria, comprising administering to a subject a therapeutically effective amount of a compound according to claim 9 , wherein the administering may be in combination with a second agent.

14. A method for treating, preventing, inhibiting, ameliorating, or eradicating malaria, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition according to claim 10 , wherein the administering may be in combination with a second agent.

15. A method for treating, preventing, inhibiting, ameliorating, or eradicating malaria, comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition according to claim 11 , wherein the administering may be in combination with a second agent.

16. The method according to claim 14 , wherein the second agent is for the treatment of malaria.

17. The method according to claim 15 , wherein the second agent is for the treatment of malaria.

18. The method according to claim 16 , wherein the second agent is an antimalarial drug selected from artemisinin, artemether, artesunate, arteflene, dihydroartemisinin, chlorproguanil, trimethoprim, chloroquine, quinine, mefloquine, amodiaquine, atovaquone, proguanil, lumefantrine, piperaquine, pyronaridine, halofantrine, pyrimethamine-sulfadoxine, quinacrine, pyrimethamine-dapsone, quinidine, amopyroquine, sulphonamides, primaquine, ferroquine, tafenoquine, arterolane, and pyronaridine.

19. The method according to claim 17 , wherein the second agent is an antimalarial drug selected from artemisinin, artemether, artesunate, arteflene, dihydroartemisinin, chlorproguanil, trimethoprim, chloroquine, quinine, mefloquine, amodiaquine, atovaquone, proguanil, lumefantrine, piperaquine, pyronaridine, halofantrine, pyrimethamine-sulfadoxine, quinacrine, pyrimethamine-dapsone, quinidine, amopyroquine, sulphonamides, primaquine, ferroquine, tafenoquine, arterolane, and pyronaridine.